Revolution Medicines, Inc. (RVMD)
- Previous Close
35.59 - Open
34.85 - Bid 34.63 x 200
- Ask 34.94 x 200
- Day's Range
34.69 - 35.20 - 52 Week Range
15.44 - 38.73 - Volume
69,634 - Avg. Volume
1,461,416 - Market Cap (intraday)
5.728B - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-3.86 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
41.58
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
www.revmed.comRecent News: RVMD
Performance Overview: RVMD
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVMD
Valuation Measures
Market Cap
5.86B
Enterprise Value
4.10B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
347.76
Price/Book (mrq)
3.21
Enterprise Value/Revenue
353.74
Enterprise Value/EBITDA
-9.52
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-20.08%
Return on Equity (ttm)
-34.75%
Revenue (ttm)
11.58M
Net Income Avi to Common (ttm)
-436.37M
Diluted EPS (ttm)
-3.86
Balance Sheet and Cash Flow
Total Cash (mrq)
1.85B
Total Debt/Equity (mrq)
4.82%
Levered Free Cash Flow (ttm)
-155.2M